For breast cancer it would already be priced more, as I believe the current SoC, doxorubicin is sold generically. So the cost base is significantly lower, so it's hard to compare what you're asking.
https://www.grandviewresearch.com/press-release/global-doxorubicin-market
i could be wrong though.
Pillar 1 - FTO (new thread), page-367
-
- There are more pages in this discussion • 2,658 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add RAC (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.53 |
Change
-0.060(3.77%) |
Mkt cap ! $260.7M | |||
| Open | High | Low | Value | Volume |
| $1.59 | $1.59 | $1.53 | $83.43K | 53.65K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 20575 | $1.53 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.57 | 300 | 1 |
View Market Depth
| Last trade - 16.10pm 16/10/2024 (20 minute delay) ? |
| RAC (ASX) Chart |